Maximilian Diehn

Jan 8, 2025 | nature.com | Jinxi Xiang |Xiyue Wang |Colin Bergstrom |Kun-Hsing Yu |Jeffrey J. Nirschl |Joel W Neal | +1 more

AbstractClinical decision-making is driven by multimodal data, including clinical notes and pathological characteristics. Artificial intelligence approaches that can effectively integrate multimodal data hold significant promise in advancing clinical care1,2. However, the scarcity of well-annotated multimodal datasets in clinical settings has hindered the development of useful models.

Sep 15, 2024 | dailyreporter.esmo.org | Maximilian Diehn

Multi-cancer early detection (MCED) tests promise to screen for multiple cancer types at the same time using a simple blood draw, potentially enabling detection of cancers without using current screening approaches and augmenting traditional screening methods such as mammography or low-dose CT scanning. Importantly, they hold the promise of diagnosing patients earlier, when the chance for cure is higher.

Aug 26, 2024 | caclubindia.com | Maximilian Diehn

During a recent move, I faced one of my worst nightmares—losing my hardware wallet containing $450,000 worth of Bitcoin. The wallet was crucial because it held all my life savings, and the realization that it was missing left me feeling utterly devastated. I searched through every box, drawer, and storage space, retracing my steps with mounting desperation. The more I looked, the more hopeless the situation seemed. The thought of losing everything I had worked so hard for was overwhelming.

Mar 22, 2024 | dailyreporter.esmo.org | Maximilian Diehn

Circulating tumour DNA (ctDNA) is an extremely flexible biomarker. In lung cancer, it has been used largely in the area of advanced disease, for example in genotyping, to identify actionable mutations and to investigate acquired mechanisms of resistance in oncogene-addicted non-small cell lung cancer (NSCLC).